Drug Trial Radar · NCT03359213
A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)
Last checked: Nov 20, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jul 26, 2018
Primary completion
Oct 4, 2019
Study completion Oct 4, 2019
Sponsor
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II open-label, randomized, parallel group, 2 sites (Brazil), designed to evaluate the safety and efficacy of 3 doses of study drug for the treatment of the MPS II.
Conditions
- Mucopolysaccharidosis II
Interventions
JR-141Drug
IV infusion (lyophilized powder), 1.0 mg/kg/week
JR-141Drug
IV infusion (lyophilized powder), 2.0 mg/kg/week
JR-141Drug
IV infusion (lyophilized powder), 4.0 mg/kg/week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse EventsTime frame: 26 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Grupo de Pesquisa Clínica em Genética Médica - HCPA
Porto Alegre, Brazil
Igeim - Unifesp
São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.